Functional validation included Tumour Immune Dysfunction and Exclusion (TIDE) analysis, Tracking Tumour Immunophenotype (TIP) profiling, in silico drug sensitivity prediction, single-cell RNA sequencing (scRNA-seq) and GPX2 knockdown experiments.<h4>Results</h4>Consensus clustering identified two reproducible immune subtypes (immune-hot and immune-cold), which were validated across seven independent immune deconvolution algorithms. The gene discussed is GPX2; the disease is neoplasm.